Sequins is a biotechnology company delivering synthetic molecular reference standards that strengthen data quality and confidence in genomics data. Built on proprietary technology, Sequins controls enable accurate measurement, benchmarking, and quality assurance for DNA and RNA assays which can be used in translational research, biomarker development, and clinical trial testing. By supporting assay reproducibility, sensitivity assessment, and cross-site comparability, Sequins partners with biotech, diagnostics developers, CROs, and clinical laboratories globally to support reliable molecular data generation and accelerate clinical development.
Why work with us
- Protects patient, study, and data integrity: Sequins solutions are designed to remain clearly distinct from clinical samples, reducing the risk of contamination, interference, or data compromise in healthcare and research settings.
- Supports strong governance and quality frameworks: Products are developed to align with verification, validation, and audit expectations, supporting quality systems and regulatory oversight within public health and clinical trial environments.
- Reduces operational and supplier risk: Platform-agnostic solutions avoid lock-in to specific technologies or vendors, supporting continuity as testing methods and suppliers change over time.
- Fit-for-purpose and adaptable: Fully synthetic designs allow controls to be tailored to current and future testing requirements, reducing the need for repeated re-procurement as assays evolve.
- Enables confidence in clinical and research decisions: Provides consistent, comparable performance monitoring to support evidence-based decision-making across sites and over time.
- Resilient, future-ready supplier: Sequins’ broad and extensible intellectual property underpins multiple applications and ongoing innovation, supporting long-term supply stability and strategic partnership.
- Collaborative and responsive: Works closely with laboratories and health organisations to support implementation, change management, and scale-up.
